IP Library › Granted Patent US 12,514,865
Granted Patent B2
US 12,514,865 · App. 17/701,270 · Granted Jan 6, 2026

Biomaterial-based antigen free vaccine and the use thereof

Inventors: Alexander J. Najibi (Cambridge, MA); Nisarg J. Shah (San Diego, MA); Hua Wang (Cambridge, MA); David J. Mooney (Sudbury, MA); David T. Scadden (Weston, MA)
Assignees: President and Fellows of Harvard College; The General Hospital Corporation
A61K31/7034A61K39/001153A61K40/19A61K40/24A61K40/42A61K40/4243A61K40/427A61P35/02A61K2039/55561
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,514,865
App. No.
17/701,270
Granted
Jan 6, 2026
Kind
B2
Abstract

Disclosed herein are vaccine compostions and method to use the same. The compositions and methods disclosed herein provide means to prevent and/or treat a variety of cancers.

Claims (36)

1 . A vaccine composition for treating a hematological malignancy, comprising:

a porous scaffold,

a cell recruitment composition, wherein the cell recruitment composition comprises a GM-CSF;

an adjuvant, wherein the adjuvant comprises a CpG-ODN;

a chemotherapeutic agent; and

a cancer antigen, wherein the cancer antigen is one or both of a WT-1 peptide or an acute myeloid leukemia cancer cell lysate, and wherein the WT-1 peptide is not from a cancer cell lysate.

2 . The vaccine composition of claim 1 , wherein the cancer antigen is a WT-1 peptide.

3 . The vaccine composition of claim 2 , wherein the cancer antigen is both of a WT-1 peptide and an acute myeloid leukemia (AML) cancer cell lysate.

4 . The vaccine composition of claim 1 , wherein the chemotherapeutic agent comprises a cytarabine, anthracycline, oxaliplatin, bortezomib, doxorubicin, daunorubicin, epirubicin, idarubicin, valrubicin or doxorubicin-iRGD.

5 . The vaccine composition of claim 1 , wherein the chemotherapeutic agent comprises a derivative or analog of cytarabine, anthracycline, oxaliplatin, bortezomib, doxorubicin, daunorubicin, epirubicin, idarubicin, valrubicin or doxorubicin-iRGD.

6 . The vaccine composition of claim 1 , wherein the composition recruits immune cells to treat a subject suffering from a hematological malignancy.

7 . The vaccine composition of claim 6 , wherein the immune cells comprise dendritic cells (DCs).

8 . The vaccine composition of claim 6 , wherein the hematological malignancy comprises Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, anaplastic large cell lymphoma, splenic marginal zone lymphoma, hepatospelenic T-cell lymphoma, angioimmunoblastic T-cell lymphoma, multiple myeloma, Waldenstrom macro globulinemia, plasmacytoma, acute lymphocytic leukemia (ALL), chronic lyphcytic leukemia (CLL), acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL), chronic idiopthic myelofibrosis (MF), chronic myelogenous leukemia (CML), T-cell prolymphocytic leukemia (T-PLL), B-cell prolymphocytic leukemia (B-PLL), chronic neutrophilic leukemia (CNL), hairy cell leukemia (HCL), T-cell large granular lymphocyte leukemia (T-LGL), and aggressive NK-cell leukemia.

9 . The vaccine composition of claim 1 , wherein the CpG-ODN is a Type A, Type B or Type C CpG-ODN.

10 . The vaccine composition of claim 1 , wherein the CpG-ODN is one or more of ODN 1585, ODN 1668, ODN 1826, ODN 2006, ODN 2006-G5, ODN 2216, ODN 2336, ODN 2395 or ODN M362.

11 . The vaccine composition of claim 1 , wherein the porous scaffold has a pore size of less than 10 nm.

12 . A method of treating an acute myeloid leukemia (AML) in a subject, comprising administering to the subject a vaccine composition, wherein the vaccine composition comprises

a porous scaffold;

a cell recruitment composition, wherein the cell recruitment composition comprises a GM-CSF;

an adjuvant, wherein the adjuvant comprises a CpG-ODN; and

a chemotherapeutic agent,

thereby treating the AML.

13 . The method of claim 12 , further comprising administering to the subject a cancer antigen.

14 . The method of claim 12 , wherein the chemotherapeutic agent comprises a cytarabine, oxiplatin, bortezomib, anthracycline and a derivative or analog thereof.

15 . The method of claim 12 , wherein the chemotherapeutic agent is selected from the group consisting of doxorubicin, doxorubicin-IRGD, daunorubicin, epirubicin, idarubicin, valrubicin, mitoxantrone and derivative or analog thereof.

16 . A method of preventing or treating an acute myeloid leukemia (AML) in a subject, comprising administering to the subject a vaccine composition, wherein the vaccine composition comprises

a scaffold;

a cell recruitment composition, wherein the cell recruitment composition comprises a GM-CSF;

an adjuvant, wherein the adjuvant comprises a CpG-ODN;

a chemotherapeutic agent; and

a cancer antigen, wherein the cancer antigen is one or both of a WT-1 peptide or an acute myeloid leukemia cancer cell lysate,

thereby preventing or treating the AML.

17 . The method of claim 16 , wherein the chemotherapeutic agent comprises a cytarabine, anthracycline, oxaliplatin, bortezomib, doxorubicin, daunorubicin, epirubicin, idarubicin, valrubicin or doxorubicin-iRGD.

18 . The method of claim 16 , wherein the chemotherapeutic agent comprises a derivative or analog of cytarabine, anthracycline, oxaliplatin, bortezomib, doxorubicin, daunorubicin, epirubicin, idarubicin, valrubicin or doxorubicin-iRGD.

19 . A method of treating a hematological malignancy in a subject, comprising administering to the subject the vaccine composition of claim 1 , thereby treating the cancer.

20 . The method of claim 19 , wherein the subject was administered a chemotherapeutic agent prior to the administration of the vaccine composition.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2023
From: SCADDEN, DAVID T
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 064057/0448 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2023
From: MOONEY, DAVID J.; NAJIBI, ALEXANDER JOSEPH; SCADDEN, DAVID T.; SHAH, NISARG J.; WANG, HUA
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 064106/0008 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2022
From: NAJIBI, ALEXANDER J.; SHAH, NISARG J.; WANG, HUA; MOONEY, DAVID J.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 060455/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2022
From: SCADDEN, DAVID T.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE; THE GENERAL HOSPITAL CORPORATION
Reel/Frame 060455/0749 →
Continuity (3)
Continuation PCTUS2020052301 · Sep 23, 2020
Provisional Application 62904446 · Sep 23, 2019
Related Publication 20220339274A1 · Oct 27, 2022
References Cited (400)
US 3773919A · Boswell et al. · 1973 [cited by applicant]
US 4522811A · Eppstein et al. · 1985 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5091513A · Huston et al. · 1992 [cited by applicant]
US 5132405A · Huston et al. · 1992 [cited by applicant]
US 5885829A · Mooney et al. · 1999 [cited by applicant]
US 5888987A · Haynes et al. · 1999 [cited by applicant]
US 5906826A · Emery et al. · 1999 [cited by applicant]
US 5951976A · Segal · 1999 [cited by applicant]
US 6129716A · Steer · 2000 [cited by applicant]
US 6160084A · Langer et al. · 2000 [cited by applicant]
US 6193970B1 · Pardoll et al. · 2001 [cited by applicant]
US 6251396B1 · Gaur et al. · 2001 [cited by applicant]
US 6281256B1 · Harris et al. · 2001 [cited by applicant]
US 6334968B1 · Shapiro et al. · 2002 [cited by applicant]
US 6352694B1 · June et al. · 2002 [cited by applicant]
US 6403374B1 · Tsien et al. · 2002 [cited by applicant]
US 6429199B1 · Krieg et al. · 2002 [cited by applicant]
US 6511511B1 · Slivka et al. · 2003 [cited by applicant]
US 6511650B1 · Eiselt et al. · 2003 [cited by applicant]
US 6541022B1 · Murphy et al. · 2003 [cited by applicant]
US 6642363B1 · Mooney et al. · 2003 [cited by applicant]
US 6685963B1 · Taupin et al. · 2004 [cited by applicant]
US 6748954B2 · Lee et al. · 2004 [cited by applicant]
US 6767928B1 · Murphy et al. · 2004 [cited by applicant]
US 6783712B2 · Slivka et al. · 2004 [cited by applicant]
US 6790840B1 · Lee et al. · 2004 [cited by applicant]
US 6797738B2 · Harris et al. · 2004 [cited by applicant]
US 6800733B2 · Tsien et al. · 2004 [cited by applicant]
US 6858222B2 · Nelson et al. · 2005 [cited by applicant]
US 6974698B1 · Miller et al. · 2005 [cited by applicant]
US 7015205B1 · Wallack et al. · 2006 [cited by applicant]
US 7157566B2 · Tsien et al. · 2007 [cited by applicant]
US 7186413B2 · Bouhadir et al. · 2007 [cited by applicant]
US 7192693B2 · Bryant et al. · 2007 [cited by applicant]
US 7244714B1 · Gonda et al. · 2007 [cited by applicant]
US 7357936B1 · Garcon · 2008 [cited by applicant]
US 7410953B2 · Kawasaki · 2008 [cited by applicant]
US 7427602B1 · Shea et al. · 2008 [cited by applicant]
US 7569850B2 · Noy et al. · 2009 [cited by applicant]
US 7575759B2 · Murphy et al. · 2009 [cited by applicant]
US 7687241B2 · Chen · 2010 [cited by applicant]
US 7709458B2 · Karaolis et al. · 2010 [cited by applicant]
US 7790699B2 · Melvik et al. · 2010 [cited by applicant]
US 8067237B2 · Mooney et al. · 2011 [cited by applicant]
US 8188058B2 · Hackam et al. · 2012 [cited by applicant]
US 8273373B2 · Alsberg et al. · 2012 [cited by applicant]
US 8354119B2 · Geistlich et al. · 2013 [cited by applicant]
US 8367628B2 · Goodwin et al. · 2013 [cited by applicant]
US 8535719B2 · Badylak et al. · 2013 [cited by applicant]
US 8709464B2 · Ma et al. · 2014 [cited by applicant]
US 8728456B2 · Sands et al. · 2014 [cited by applicant]
US 8883308B2 · Polshettiwar et al. · 2014 [cited by applicant]
US 8932583B2 · Mooney et al. · 2015 [cited by applicant]
US 9012399B2 · Cao et al. · 2015 [cited by applicant]
US 9132210B2 · Mooney et al. · 2015 [cited by applicant]
US 9139809B2 · Porcelli et al. · 2015 [cited by applicant]
US 9150631B2 · Super et al. · 2015 [cited by applicant]
US 9370558B2 · Ali et al. · 2016 [cited by applicant]
US 9381235B2 · Sands et al. · 2016 [cited by applicant]
US 9446107B2 · Mooney et al. · 2016 [cited by applicant]
US 9486512B2 · Kim et al. · 2016 [cited by applicant]
US 9591360B2 · Jennings et al. · 2017 [cited by applicant]
US 9610328B2 · Mooney et al. · 2017 [cited by applicant]
US 9675561B2 · Bencherif et al. · 2017 [cited by applicant]
US 9770535B2 · Mooney et al. · 2017 [cited by applicant]
US 9821045B2 · Ali et al. · 2017 [cited by applicant]
US 9937249B2 · Kim et al. · 2018 [cited by applicant]
US 10045947B2 · Bencherif et al. · 2018 [cited by applicant]
US 10080789B2 · Sands et al. · 2018 [cited by applicant]
US 10137184B2 · Mooney et al. · 2018 [cited by applicant]
US 10149897B2 · Mooney et al. · 2018 [cited by applicant]
US 10258677B2 · Mooney et al. · 2019 [cited by applicant]
US 10328133B2 · Mooney et al. · 2019 [cited by applicant]
US 10406216B2 · Kim et al. · 2019 [cited by applicant]
US 10568949B2 · Ali et al. · 2020 [cited by applicant]
US 10682400B2 · Ali et al. · 2020 [cited by applicant]
US 10813988B2 · Super et al. · 2020 [cited by applicant]
US 11059050B2 · Kang et al. · 2021 [cited by applicant]
US 11096997B2 · Mooney et al. · 2021 [cited by applicant]
US 11150242B2 · Ali et al. · 2021 [cited by applicant]
US 11202759B2 · Huebsch et al. · 2021 [cited by applicant]
US 11278604B2 · Kim et al. · 2022 [cited by applicant]
US 20020045672A1 · Harris et al. · 2002 [cited by applicant]
US 20020131853A1 · Nagasawa · 2002 [cited by applicant]
US 20020131953A1 · Takashima et al. · 2002 [cited by applicant]
US 20020150604A1 · Yi et al. · 2002 [cited by applicant]
US 20030075822A1 · Slivka et al. · 2003 [cited by applicant]
US 20030082806A1 · Berenson et al. · 2003 [cited by applicant]
US 20030095994A1 · Geistlich et al. · 2003 [cited by applicant]
US 20030100527A1 · Krieg et al. · 2003 [cited by applicant]
US 20030194397A1 · Mishra · 2003 [cited by applicant]
US 20030232895A1 · Omidian et al. · 2003 [cited by applicant]
US 20030235557A1 · Gaiger et al. · 2003 [cited by applicant]
US 20040028745A1 · Bouhadir et al. · 2004 [cited by applicant]
US 20040043034A1 · Jensenius et al. · 2004 [cited by applicant]
US 20040058883A1 · Phillips et al. · 2004 [cited by applicant]
US 20040063206A1 · Rowley et al. · 2004 [cited by applicant]
US 20040136968A1 · Zheng et al. · 2004 [cited by applicant]
US 20040151764A1 · Zamora · 2004 [cited by applicant]
US 20040213795A1 · Collins et al. · 2004 [cited by applicant]
US 20040220111A1 · Kleinman et al. · 2004 [cited by applicant]
US 20040228858A1 · Hanson et al. · 2004 [cited by applicant]
US 20040242469A1 · Lee et al. · 2004 [cited by applicant]
US 20040242482A1 · Gehring et al. · 2004 [cited by applicant]
US 20050002915A1 · Atala et al. · 2005 [cited by applicant]
US 20050037330A1 · Fischer et al. · 2005 [cited by applicant]
US 20050053667A1 · Irvine et al. · 2005 [cited by applicant]
US 20050079159A1 · Shastri et al. · 2005 [cited by applicant]
US 20050090008A1 · Segura et al. · 2005 [cited by applicant]
US 20050106211A1 · Nelson et al. · 2005 [cited by applicant]
US 20050154376A1 · Riviere et al. · 2005 [cited by applicant]
US 20050177249A1 · Kladakis et al. · 2005 [cited by applicant]
US 20050202394A1 · Dobson · 2005 [cited by applicant]
US 20060083712A1 · Anversa · 2006 [cited by applicant]
US 20060141018A1 · Cochrum et al. · 2006 [cited by applicant]
US 20060264380A1 · Hellstrom et al. · 2006 [cited by applicant]
US 20060292134A1 · Stohs · 2006 [cited by applicant]
US 20070003595A1 · Wang et al. · 2007 [cited by applicant]
US 20070020232A1 · Rossignol et al. · 2007 [cited by applicant]
US 20070026518A1 · Healy et al. · 2007 [cited by applicant]
US 20070081972A1 · Sandler et al. · 2007 [cited by applicant]
US 20070116680A1 · Stegemann et al. · 2007 [cited by applicant]
US 20070178159A1 · Chen et al. · 2007 [cited by applicant]
US 20070190646A1 · Engler et al. · 2007 [cited by applicant]
US 20080044900A1 · Mooney et al. · 2008 [cited by applicant]
US 20080044990A1 · Lee · 2008 [cited by applicant]
US 20080051490A1 · Williams et al. · 2008 [cited by applicant]
US 20080113929A1 · Lipford et al. · 2008 [cited by applicant]
US 20080138416A1 · Rauh et al. · 2008 [cited by applicant]
US 20080152624A1 · Paludan et al. · 2008 [cited by applicant]
US 20080159993A1 · Stauss et al. · 2008 [cited by applicant]
US 20080206308A1 · Jabbari et al. · 2008 [cited by applicant]
US 20080233181A1 · Nagy et al. · 2008 [cited by applicant]
US 20080268019A1 · Badylak et al. · 2008 [cited by applicant]
US 20080268052A1 · Voytik-Harbin et al. · 2008 [cited by applicant]
US 20090017096A1 · Lowman et al. · 2009 [cited by applicant]
US 20090041825A1 · Kotov et al. · 2009 [cited by applicant]
US 20090192079A1 · Santos et al. · 2009 [cited by applicant]
US 20090238853A1 · Liu et al. · 2009 [cited by applicant]
US 20090252752A1 · Tahara et al. · 2009 [cited by applicant]
US 20090297551A1 · Sattentau et al. · 2009 [cited by applicant]
US 20090297579A1 · Semino et al. · 2009 [cited by applicant]
US 20090305983A1 · Ying et al. · 2009 [cited by applicant]
US 20100015709A1 · Rehfeldt et al. · 2010 [cited by applicant]
US 20100055102A1 · Langermann · 2010 [cited by applicant]
US 20100055186A1 · Dadsetan et al. · 2010 [cited by applicant]
US 20100080816A1 · Hadeiba et al. · 2010 [cited by applicant]
US 20100129422A1 · Han et al. · 2010 [cited by applicant]
US 20100159008A1 · Barron et al. · 2010 [cited by applicant]
US 20100174346A1 · Boyden et al. · 2010 [cited by applicant]
US 20100189760A1 · Schaffer et al. · 2010 [cited by applicant]
US 20100190741A1 · Cohen et al. · 2010 [cited by applicant]
US 20100272771A1 · Harlow et al. · 2010 [cited by applicant]
US 20110008443A1 · Alsberg et al. · 2011 [cited by applicant]
US 20110020216A1 · Mooney et al. · 2011 [cited by applicant]
US 20110117170A1 · Cao et al. · 2011 [cited by applicant]
US 20110159023A1 · Langermann · 2011 [cited by applicant]
US 20110207166A1 · Vaiselbuh · 2011 [cited by applicant]
US 20110223255A1 · Thiesen et al. · 2011 [cited by applicant]
US 20110253643A1 · Polshettiwar et al. · 2011 [cited by applicant]
US 20110256184A1 · Lei et al. · 2011 [cited by applicant]
US 20110300186A1 · Hellstrom et al. · 2011 [cited by applicant]
US 20120040011A9 · Boons et al. · 2012 [cited by applicant]
US 20120100182A1 · Mooney et al. · 2012 [cited by applicant]
US 20120121539A1 · Sands et al. · 2012 [cited by applicant]
US 20120122218A1 · Huebsch et al. · 2012 [cited by applicant]
US 20120134967A1 · Mooney et al. · 2012 [cited by applicant]
US 20120256336A1 · Yano et al. · 2012 [cited by applicant]
US 20120264599A1 · Komatsu et al. · 2012 [cited by applicant]
US 20120294888A1 · Kishimoto et al. · 2012 [cited by applicant]
US 20120329791A1 · Ashwell et al. · 2012 [cited by applicant]
US 20130029030A1 · Larsen · 2013 [cited by applicant]
US 20130035283A1 · Super et al. · 2013 [cited by applicant]
US 20130045246A1 · Edwards et al. · 2013 [cited by applicant]
US 20130052117A1 · Imai et al. · 2013 [cited by applicant]
US 20130072547A1 · Hackam et al. · 2013 [cited by applicant]
US 20130145488A1 · Wang et al. · 2013 [cited by applicant]
US 20130202707A1 · Ali et al. · 2013 [cited by applicant]
US 20130251784A1 · Kim et al. · 2013 [cited by applicant]
US 20130302396A1 · Mooney et al. · 2013 [cited by applicant]
US 20130331343A1 · Cao et al. · 2013 [cited by applicant]
US 20140072510A1 · Shea et al. · 2014 [cited by applicant]
US 20140112990A1 · Bencherif et al. · 2014 [cited by applicant]
US 20140178964A1 · Mooney et al. · 2014 [cited by applicant]
US 20140193488A1 · Kim et al. · 2014 [cited by applicant]
US 20140227327A1 · Bencherif et al. · 2014 [cited by applicant]
US 20140227723A1 · Ingber et al. · 2014 [cited by applicant]
US 20140234423A1 · Sands et al. · 2014 [cited by applicant]
US 20150024026A1 · Mooney et al. · 2015 [cited by applicant]
US 20150030669A1 · Platscher et al. · 2015 [cited by applicant]
US 20150072009A1 · Kim et al. · 2015 [cited by applicant]
US 20150080321A1 · Li et al. · 2015 [cited by applicant]
US 20150094518A1 · Wu et al. · 2015 [cited by applicant]
US 20150359928A1 · Gu et al. · 2015 [cited by applicant]
US 20150366956A1 · Mooney et al. · 2015 [cited by applicant]
US 20160033511A1 · Pannell et al. · 2016 [cited by applicant]
US 20160129053A1 · Brass et al. · 2016 [cited by applicant]
US 20160220668A1 · Mooney et al. · 2016 [cited by applicant]
US 20160228543A1 · Mooney et al. · 2016 [cited by applicant]
US 20160271298A1 · Mooney et al. · 2016 [cited by applicant]
US 20160279219A1 · Mooney et al. · 2016 [cited by applicant]
US 20160279220A1 · Mooney et al. · 2016 [cited by applicant]
US 20160296611A1 · Ali et al. · 2016 [cited by applicant]
US 20170362307A1 · Ingber et al. · 2017 [cited by applicant]
US 20170368169A1 · Loew et al. · 2017 [cited by applicant]
US 20180021253A1 · Sandeep et al. · 2018 [cited by applicant]
US 20180117171A1 · Mooney et al. · 2018 [cited by applicant]
US 20180243231A1 · Bencherif et al. · 2018 [cited by applicant]
US 20180298047A1 · Cheng et al. · 2018 [cited by applicant]
US 20180320157A1 · Super et al. · 2018 [cited by applicant]
US 20180326073A1 · Mooney et al. · 2018 [cited by applicant]
US 20180371058A1 · Watters et al. · 2018 [cited by applicant]
US 20190060525A1 · Shah et al. · 2019 [cited by applicant]
US 20190076373A1 · Bencherif et al. · 2019 [cited by applicant]
US 20190183992A1 · Sands et al. · 2019 [cited by applicant]
US 20190216910A1 · Mooney et al. · 2019 [cited by applicant]
US 20190290696A1 · De Miroschedji · 2019 [cited by applicant]
US 20190292517A1 · Cheung et al. · 2019 [cited by applicant]
US 20190367550A1 · Cheng et al. · 2019 [cited by applicant]
US 20200024339A1 · Springer et al. · 2020 [cited by applicant]
US 20200206333A1 · Shah et al. · 2020 [cited by applicant]
US 20200276290A1 · Ali et al. · 2020 [cited by applicant]
US 20200297854A1 · Ingber et al. · 2020 [cited by applicant]
US 20210170007A1 · Super et al. · 2021 [cited by applicant]
US 20210205233A1 · Bencherif et al. · 2021 [cited by applicant]
US 20220047778A1 · Shah et al. · 2022 [cited by applicant]
US 20220107308A1 · Ali et al. · 2022 [cited by applicant]
AU 2014200405A1 · 2014 [cited by applicant]
AU 2018201930A1 · 2018 [cited by applicant]
CN 1487839A · 2004 [cited by applicant]
CN 1527697A · 2004 [cited by applicant]
CN 1757662A · 2006 [cited by applicant]
CN 101584612A · 2009 [cited by applicant]
CN 101655611A · 2010 [cited by applicant]
CN 101829361A · 2010 [cited by applicant]
CN 102000689A · 2011 [cited by applicant]
CN 102006891A · 2011 [cited by applicant]
CN 102170903A · 2011 [cited by applicant]
CN 102947341A · 2013 [cited by applicant]
CN 103237885A · 2013 [cited by applicant]
CN 104411331A · 2015 [cited by applicant]
EP 0562862A1 · 1993 [cited by applicant]
EP 1452191A2 · 2004 [cited by applicant]
EP 1561481A2 · 2005 [cited by applicant]
EP 1712238A1 · 2006 [cited by applicant]
EP 1975230A1 · 2008 [cited by applicant]
EP 2254602A2 · 2010 [cited by applicant]
JP 2000503884A · 2000 [cited by applicant]
JP 2001049018A · 2001 [cited by applicant]
JP 2001524136A · 2001 [cited by applicant]
JP 2003506401A · 2003 [cited by applicant]
JP 2003180815A · 2003 [cited by applicant]
JP 2004159849A · 2004 [cited by applicant]
JP 2004520043A · 2004 [cited by applicant]
JP 2005160669A · 2005 [cited by applicant]
JP 2005168760A · 2005 [cited by applicant]
JP 2005170816A · 2005 [cited by applicant]
JP 2005528401A · 2005 [cited by applicant]
JP 2007500673A · 2007 [cited by applicant]
JP 2007503881A · 2007 [cited by applicant]
JP 2007505827A · 2007 [cited by applicant]
JP 2007528848A · 2007 [cited by applicant]
JP 2008515503A · 2008 [cited by applicant]
JP 2008528114A · 2008 [cited by applicant]
JP 2009519042A · 2009 [cited by applicant]
JP 2009521406A · 2009 [cited by applicant]
JP 2009540921A · 2009 [cited by applicant]
JP 2010502824A · 2010 [cited by applicant]
JP 2010508976A · 2010 [cited by applicant]
JP 2010227012A · 2010 [cited by applicant]
JP 2011511684A · 2011 [cited by applicant]
JP 2011511834A · 2011 [cited by applicant]
JP 2013531043A · 2013 [cited by applicant]
JP 2015503626A · 2015 [cited by applicant]
JP 2015516398A · 2015 [cited by applicant]
JP 2018117680A · 2018 [cited by applicant]
WO WO199602555A1 · 1996 [cited by applicant]
WO WO199616086A1 · 1996 [cited by applicant]
WO WO1998012228A1 · 1998 [cited by applicant]
WO WO199816266A1 · 1998 [cited by applicant]
WO WO199944583A2 · 1999 [cited by applicant]
WO WO199951259A2 · 1999 [cited by applicant]
WO WO199952356A1 · 1999 [cited by applicant]
WO WO200050006A2 · 2000 [cited by applicant]
WO WO200110421A1 · 2001 [cited by applicant]
WO WO200135932A2 · 2001 [cited by applicant]
WO WO200137810A2 · 2001 [cited by applicant]
WO WO200216557A2 · 2002 [cited by applicant]
WO WO200240071A1 · 2002 [cited by applicant]
WO WO2002058723A2 · 2002 [cited by applicant]
WO WO2002092054A2 · 2002 [cited by applicant]
WO WO2003020161A2 · 2003 [cited by applicant]
WO WO2003020884A2 · 2003 [cited by applicant]
WO WO2003070291A1 · 2003 [cited by applicant]
WO WO2003088905A2 · 2003 [cited by applicant]
WO WO2004006990A2 · 2004 [cited by applicant]
WO WO2004029230A2 · 2004 [cited by applicant]
WO WO2004030706A2 · 2004 [cited by applicant]
WO WO2004031371A2 · 2004 [cited by applicant]
WO WO2004089413A1 · 2004 [cited by applicant]
WO WO2005013896A2 · 2005 [cited by applicant]
WO WO2005013933A1 · 2005 [cited by applicant]
WO WO2005020849A2 · 2005 [cited by applicant]
WO WO2005025614A2 · 2005 [cited by applicant]
WO WO2005026318A2 · 2005 [cited by applicant]
WO WO2005037190A2 · 2005 [cited by applicant]
WO WO2005037293A1 · 2005 [cited by applicant]
WO WO2005046748A1 · 2005 [cited by applicant]
WO WO2005072088A2 · 2005 [cited by applicant]
WO WO2005104755A2 · 2005 [cited by applicant]
WO WO2006039045A2 · 2006 [cited by applicant]
WO WO2006040128A1 · 2006 [cited by applicant]
WO WO2006078987A2 · 2006 [cited by applicant]
WO WO2006113407A2 · 2006 [cited by applicant]
WO WO2006119619A1 · 2006 [cited by applicant]
WO WO2006136905A2 · 2006 [cited by applicant]
WO WO2007001332A2 · 2007 [cited by applicant]
WO WO2007030901A1 · 2007 [cited by applicant]
WO WO2007039150A2 · 2007 [cited by applicant]
WO WO2007042554A2 · 2007 [cited by applicant]
WO WO2007051120A2 · 2007 [cited by applicant]
WO WO2007063075A1 · 2007 [cited by applicant]
WO WO2007064152A1 · 2007 [cited by applicant]
WO WO2007068489A2 · 2007 [cited by applicant]
WO WO2007070660A2 · 2007 [cited by applicant]
WO WO2007078196A1 · 2007 [cited by applicant]
WO WO2007087585A1 · 2007 [cited by applicant]
WO WO2007089870A2 · 2007 [cited by applicant]
WO WO2007107739A1 · 2007 [cited by applicant]
WO WO2007149161A2 · 2007 [cited by applicant]
WO WO2007150020A1 · 2007 [cited by applicant]
WO WO2008008266A2 · 2008 [cited by applicant]
WO WO2008018707A1 · 2008 [cited by applicant]
WO WO2008031525A1 · 2008 [cited by applicant]
WO WO2008043157A1 · 2008 [cited by applicant]
WO WO2008057600A2 · 2008 [cited by applicant]
WO WO2008109852A2 · 2008 [cited by applicant]
WO WO2008114149A2 · 2008 [cited by applicant]
WO WO2008148761A1 · 2008 [cited by applicant]
WO WO2008157394A2 · 2008 [cited by applicant]
WO WO2009002401A2 · 2008 [cited by applicant]
WO WO2009005769A2 · 2009 [cited by applicant]
WO WO2009018500A1 · 2009 [cited by applicant]
WO WO2009024775A1 · 2009 [cited by applicant]
WO WO2009072767A2 · 2009 [cited by applicant]
WO WO2009074341A1 · 2009 [cited by applicant]
WO WO2009100716A2 · 2009 [cited by applicant]
WO WO2009102465A2 · 2009 [cited by applicant]
WO WO2009146456A1 · 2009 [cited by applicant]
WO WO2009155583A1 · 2009 [cited by applicant]
WO WO2010078209A2 · 2010 [cited by applicant]
WO WO2010120749A2 · 2010 [cited by applicant]
WO WO2011014871A1 · 2011 [cited by applicant]
WO WO2011043834A1 · 2011 [cited by applicant]
WO WO2011043835A1 · 2011 [cited by applicant]
WO WO2011063336A2 · 2011 [cited by applicant]
WO WO2011109834A2 · 2011 [cited by applicant]
WO WO2011130753A2 · 2011 [cited by applicant]
WO WO2011150240A1 · 2011 [cited by applicant]
WO WO2011151431A1 · 2011 [cited by applicant]
WO WO2011163669A2 · 2011 [cited by applicant]
WO WO2012009611A2 · 2012 [cited by applicant]
WO WO2012019049A1 · 2012 [cited by applicant]
WO WO2012048165A2 · 2012 [cited by applicant]
WO WO2012064697A2 · 2012 [cited by applicant]
WO WO2012148684A1 · 2012 [cited by applicant]
WO WO2012149358A1 · 2012 [cited by applicant]
WO WO2012167230A1 · 2012 [cited by applicant]
WO WO2013012924A2 · 2013 [cited by applicant]
WO WO2013106852A1 · 2013 [cited by applicant]
WO WO2013158673A1 · 2013 [cited by applicant]
WO WO2013172967A1 · 2013 [cited by applicant]
WO WO2013190555A1 · 2013 [cited by applicant]
WO WO2014063128A1 · 2014 [cited by applicant]
WO WO2014189805A1 · 2014 [cited by applicant]
WO WO2014190229A1 · 2014 [cited by applicant]
WO WO2015066535A1 · 2015 [cited by applicant]
WO WO2015154078A1 · 2015 [cited by applicant]
WO WO2015168379A2 · 2015 [cited by applicant]
WO WO2016004068A1 · 2016 [cited by applicant]
WO WO2016123573A1 · 2016 [cited by applicant]
WO WO2016161372A1 · 2016 [cited by applicant]
WO WO2017136837A1 · 2017 [cited by applicant]
WO WO2017143024A2 · 2017 [cited by applicant]
WO WO2018013797A1 · 2018 [cited by applicant]
WO WO2018026884A1 · 2018 [cited by applicant]
WO WO2018144966A1 · 2018 [cited by applicant]
WO WO2018170414A1 · 2018 [cited by applicant]
WO WO2018213631A1 · 2018 [cited by applicant]
WO WO2018227205A1 · 2018 [cited by applicant]
WO WO2020061129A1 · 2020 [cited by applicant]
WO WO2021155297A1 · 2021 [cited by applicant]
Ali et al. The efficacy of intracranial PLG-based vaccines is dependent on direct implantation into brain tissue. Journal of Controlled Release 154 (2011) 249-257. [cited by examiner]
Chew et al. Biomaterial-Based Implantable Devices for Cancer Therapy. Adv. Healthcare Mater. 2017, 6, 1600766. [cited by examiner]
Chong et al. Combining cancer vaccines with chemotherapy. Expert Opin. Pharmacother. (2005) 6(16):2813-2820. [cited by examiner]
Sakai et al. Clinical effect and immunological response in patients with advanced malignant glioma treated withWT1-pulsed dendritic cell-based immunotherapy: A report of two cases. Interdisciplinary Neurosurgery: Advanc… [cited by examiner]
Abrahams et al., Expression and secretion of antiviral factors by trophoblast cells following stimulation by the TLR-3 agonist, Poly(I : C). Hum Reprod. Sep. 2006;21(9):2432-9. [cited by applicant]
Agache et al., Mechanical properties and Young's modulus of human skin in vivo. Arch Dermatol Res. 1980;269(3):221-32. [cited by applicant]
Agrawal et al., Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein… [cited by applicant]